Development of an Epigenetic Biomarker for Prediction of Fetal Alcohol Spectrum Disorder

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

600 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-04-12

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of the study is to validate epigenetic changes as biomarkers in a prospective sampling of newborn blood samples collected at birth (umbilical cord blood) and during routine screening (heel stick blood) in newborns concurrently tested for alcohol exposure levels by PEth blood spot testing.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prenatal Alcohol Biomarker Study in Uruguay

NCT02600624

Fetal Alcohol Syndrome

COMPLETED

Impact of Maternal-infant Therapeutics on Safety, Mortality, and Disability

NCT01028183

Gastroesophageal Reflux Presumed Sepsis Patent Ductus Arteriosus +2 more

WITHDRAWN

Examining a New Biomarker of Nicotine Use Among Pregnant Women Who Participated in the New England SCRIPT

NCT00519766

Smoking Tobacco Use Disorder

COMPLETED

Embryo Health Study

NCT04528498

Infertility Hereditary Diseases

RECRUITING

Impact of Electronic Cigarettes on Perinatal Immune Responsiveness and Birth Outcomes

NCT02553577

Immune Response Birth Weight Gestational Age

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Fetal alcohol spectrum disorders (FASD) are a group of conditions that can occur in a person whose birth mother consumed alcohol during pregnancy. The effects can include physical problems and/or difficulties with behavior and learning. When clinicians identify FASD early, intervention approaches can minimize the potential impact and lessen or even prevent disabilities. Thus, objective markers for prenatal alcohol exposure are desired.

Using dried blood spots from the umbilical cord and a heel stick of newborns, this study will use Phosphatidylethanol (PEth), a novel biomarker for alcohol exposure, to identify and characterize infants' exposure to alcohol before birth. Additionally, the dried blood spots will used to validate the use of screening assays using epigenetic changes as markers for prenatal alcohol exposure. Epigenetic changes are heritable changes in DNA that affect DNA function but do not change DNA sequence. The use of PEth testing will allow for the correlation of prenatal alcohol exposure levels with epigenetic changes. Women will be consented prior to delivery for participation in this prospective study. The study will be conducted in collaboration with United States Drug Testing Laboratories, Inc. (USDTL).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fetal Alcohol Spectrum Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Newborn infants

Neonates born from consented women at the study hospital

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women aged ≥ 18 years and currently pregnant at time of enrollment
* Women who plan to and then deliver their infants at CAMC Women and Children's Hospital

* Birth mother was consented prior to delivery
* Live birth at CAMC Women and Children's Hospital

Exclusion Criteria

* Women aged \< 18 years
* Women not pregnant
* Women who do not plan to deliver or did not end up delivering their infants at CAMC Women and Children's Hospital

Infants:

* Birth mother was NOT consented prior to delivery
* Stillborn

Eligible Sex

ALL

Accepts Healthy Volunteers

No